Method for identification and quantification of intact teduglutide peptide using (RP)UHPLC-UV-(HESI/ORBITRAP)MS

• Published in: Analytical methods 2022-11, Vol.14 (43), p.4359-4369
• Main Authors: Pérez-Robles, Raquel, Salmerón-García, Antonio, Clemente-Bautista, Susana, Jiménez-Lozano, Inés, Cabañas-Poy, María Josep, Cabeza, Jose, Navas, Natalia
• Format: Article
• Language: English
• Subjects: Chemical compounds; Chromatography, High Pressure Liquid - methods; Degradation; Glucagon; Glucagon-like peptide 2; Glucagon-Like Peptide 2 - therapeutic use; Humans; Intestine; Light effects; Peptides; Peptides - therapeutic use; Pharmacology; Post-translation; Shaking; Short bowel syndrome; Short Bowel Syndrome - drug therapy; Structural analysis
• ISSN: 1759-9660; 1759-9679
• DOI: 10.1039/d2ay01254e

Teduglutide (Revestive®, 10 mg mL −1 ) is a recombinant human glucagon-like peptide 2 analogue, used in the treatment of short bowel syndrome, a serious and highly disabling condition which results from either too small a length of intestine or loss of critical intestinal function. The determination of therapeutic compounds of protein-nature is always challenging due to their complex structure. In this work, we present a fast, straightforward reversed phase (RP)UHPLC-UV-(HESI/ORBITRAP)MS method for the identification and quantification of the intact teduglutide peptide. The method has been developed and validated in accordance with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines; therefore, linearity, limits of detection and quantification, accuracy (precision and trueness), robustness, system suitability and specificity using the signal from the UV and MS, have been evaluated. The validation performance parameters obtained from the UV and MS signals were compared throughout the work, to select the most suitable. To study the specificity of the method and the impact of medicine mishandling under hospital conditions, force degradation studies were performed, i.e. thermal (40 °C and 60 °C), shaking (mechanical) and light (accelerated exposition) effects. Identification by the exact mass of teduglutide was achieved and it was confirmed that the peptide does not undergo any post-translational modifications (PTMs). To the best of our knowledge, the present work reports the first method developed for the simultaneous identification, structural characterization, and quantification of the therapeutic teduglutide peptide. Finally, the proposed method is able to indicate stability when quantifying the intact teduglutide since detects and characterises the exact mass of the degradation/modification products. The present work reports the first method for the simultaneous identification, structural characterization, and quantification of the therapeutic teduglutide peptide.